Citadel Advisors’s Plus Therapeutics PSTV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-7,402
| Closed | -$94.8K | – | 13976 |
|
|
2025
Q4 | $94.8K | Buy |
+7,402
| New | +$112K | ﹤0.01% | 11689 |
|
|
2024
Q3 | – | Sell |
-731
| Closed | -$26.9K | – | 15023 |
|
|
2024
Q2 | $26.9K | Buy |
731
+303
| +71% | +$14.9K | ﹤0.01% | 12376 |
|
|
2024
Q1 | $19.3K | Sell |
428
-246
| -36% | -$11.9K | ﹤0.01% | 13039 |
|
|
2023
Q4 | $30.1K | Buy |
+674
| New | +$27K | ﹤0.01% | 12261 |
|
|
2022
Q4 | – | Sell |
-45
| Closed | -$7K | – | 15331 |
|
|
2022
Q3 | $7K | Buy |
+45
| New | +$10K | ﹤0.01% | 12326 |
|
|
2022
Q1 | – | Sell |
-222
| Closed | -$87K | – | 14377 |
|
|
2021
Q4 | $87K | Buy |
+222
| New | +$128K | ﹤0.01% | 12847 |
|
|
2021
Q3 | – | Sell |
-116
| Closed | -$111K | – | 14469 |
|
|
2021
Q2 | $111K | Buy |
+116
| New | +$105K | ﹤0.01% | 12824 |
|
|
2021
Q1 | – | Sell |
-33
| Closed | -$25K | – | 13607 |
|
|
2020
Q4 | $25K | Sell |
33
-27
| -45% | -$23.1K | ﹤0.01% | 10745 |
|
|
2020
Q3 | $58K | Buy |
+60
| New | +$58.2K | ﹤0.01% | 9546 |
|
|
2020
Q1 | – | Sell |
-42
| Closed | -$37K | – | 10034 |
|
|
2019
Q4 | $37K | Buy |
+42
| New | +$38.5K | ﹤0.01% | 8823 |
|
|
2019
Q3 | – | Sell |
-2
| Closed | -$9K | – | 9639 |
|
|
2019
Q2 | $9K | Buy |
2
+1
| +100% | +$5.16K | ﹤0.01% | 9043 |
|
|
2019
Q1 | $6K | Buy |
+1
| New | +$5.28K | ﹤0.01% | 9171 |
|
|
2018
Q1 | – | Hold |
0
| – | -$6K | – | 8672 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7907 |
|
|
2017
Q2 | – | Hold |
0
| – | -$25K | – | 7940 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 7202 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6840 |
|
|
2016
Q2 | – | Hold |
0
| – | -$10K | – | 7275 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6596 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 8583 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 8739 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 8623 |
|
|
2015
Q1 | – | Hold |
0
| – | -$13K | – | 8780 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 8042 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 7879 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 6065 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 7983 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 6219 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 5727 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 5519 |
|
Other funds holding PSTV
VCM
VFT
TSS
XT
Citadel Advisors's PSTV Position: Q1 2026 in Review
Citadel Advisors sold out of Plus Therapeutics (PSTV) in Q1 2026, closing a stake of 7,402 shares — an estimated $94.8K sold.
Citadel Advisors first reported a position in PSTV in Q1 2019 and held it in 12 quarters. The position peaked at $111K in Q2 2021. 23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.
- Citadel Advisors reported no remaining Plus Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 7,402 Plus Therapeutics shares in Q1 2026, an estimated $94.8K.
- Citadel Advisors first reported a position in Plus Therapeutics in Q1 2019 and held it in 12 quarters.
- Citadel Advisors's Plus Therapeutics position peaked at $111K in Q2 2021.
- 23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.